Every Form 4 that Hoth Therapeutics, Inc. (HOTH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HOTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HOTH filings page.
Rocket One Inc. director Wayne Linsley received an equity award in the form of stock options. On May 26, 2026, he was granted 75,000 options to acquire common stock at an exercise price of $0.7083 per share.
The options were issued under the company’s Amended and Restated 2022 Omnibus Equity Incentive Plan and vested in full upon grant, meaning they became fully exercisable immediately. Following this award, Linsley holds 75,000 options directly, with an expiration date of May 26, 2036. This filing reflects a compensation-related grant, not an open-market purchase or sale of Rocket One shares.
Rocket One Inc. reported that CEO and President Robb Knie received a grant of stock options as compensation. He was awarded 550,000 options to purchase Rocket One common stock at an exercise price of $0.7083 per share. The options were issued under the company’s Amended and Restated 2022 Omnibus Equity Incentive Plan and vested in full upon grant on May 26, 2026. They are scheduled to expire on May 26, 2036. Following this award, Knie holds 550,000 options directly, giving him the right to acquire an equal number of common shares in the future but involving no open-market buying or selling.
Rocket One Inc. director David Sarnoff received a grant of 75,000 stock options as compensation. These options were awarded at an exercise price of $0.7083 per share and relate to 75,000 shares of common stock. The grant was made under Rocket One Inc.’s Amended and Restated 2022 Omnibus Equity Incentive Plan.
The options vested in full on the grant date, meaning Sarnoff’s right to exercise them is fully earned immediately, and they are scheduled to expire on May 26, 2036. Following this grant, he directly holds 75,000 options, with no open-market share purchases or sales reported in this filing.
Rocket One Inc. director Christopher Michael Camarra received an award of options covering 75,000 shares of common stock. The options have an exercise price of $0.7083 per share, vest in full immediately upon grant, and expire on May 26, 2036. Following this grant, he holds 75,000 options directly.
Rocket One Inc. director Jeff Pavell received a grant of stock options that give him the right to acquire 75,000 shares of Common Stock. The options have an exercise price of $0.7083 per share and expire on May 26, 2036.
The options were issued under the Rocket One Inc. Amended and Restated 2022 Omnibus Equity Incentive Plan and vested in full upon grant, meaning they are immediately exercisable. Following this grant, Pavell holds 75,000 options directly.